Atazanavir

Atazanavir is an azapeptide inhibitor of HIV-1 protease (Ki = 2.66 nM). It has antiviral activity against a variety of HIV-1 strains in several cell types with EC50 values ranging from 2.62 to 5.28 nM. Atazanavir exhibits a minor synergistic effect when used in combination with the reverse transcriptase inhibitor zidovudine (Cay-15492) in HIV-1-infected human peripheral blood mononuclear cells (PBMCs) and an additive effect when used in combination with several additional reverse transcriptase or HIV-1 protease inhibitors. Atazanavir also inhibits UDP-glucuronyltransferase 1A1 (UGT1A1), which is involved in bilirubin clearance. Formulations containing atazanavir have been used in combination therapy for the treatment of HIV-1 infection.Formal Name: 3S,12S-bis(1,1-dimethylethyl)-8S-hydroxy-4,11-dioxo-9S-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid, 1,14-dimethyl ester. CAS Number: 198904-31-3. Synonyms: BMS 232632, CGP 73547. Molecular Formula: C38H52N6O7. Formula Weight: 704.9. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 25 mg/ml, DMF:PBS (pH 7.2) (1:8): 0.1 mg/ml, DMSO: 16 mg/ml, Ethanol: 2 mg/ml. lambdamax: 251, 280 nm. SMILES: COC(N[C@@H](C(C)(C)C)C(N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC2=CC=C(C3=NC=CC=C3)C=C2)NC([C@@H](NC(OC)=O)C(C)(C)C)=O)=O)=O. InChi Code: InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,. InChi Key: AXRYRYVKAWYZBR-GASGPIRDSA-N.